faqs.org » Abstracts Index » Abstracts » Business, international

LUPIN LABORATORIES HOLDS 40% SHARE IN ANTI-TB FORMULATIONS MARKET

Article Abstract:

Lupin Laboratories, in which Mr Desh Bandhu Gupta and associates hold 75 percent stake, is the largest manufacturer of anti-tuberculosis drugs. It holds 40 percent share in the formulations segment. The promoter is planning to divest 10 percent of his stake in the company. It is shortly acquiring Eli Lilly's cephalosporin unit in Puerto Rico. It also plans to buy out a unit from Max-GB in the domestic market. It plans to target generic market in the West with cefotaxime, ceftriaxone, ceftazidine, cefaclor, cefalexin and cefadroxyl. For 1997-98, the company has posted a net profit of $8.1 million on sales of $164 million. (gs)

Comment:

Is the largest manufacturer of anti-tuberculosis drugs, holding 40% share in the formulations segment

Sales & consumption, Tuberculostatic Preparations, Antitubercular agents, Article, Lupin Laboratories

---

TBL IN TALKS WITH MNCS TO SELL TRANSGENE VACCINE

Article Abstract:

Transgene Biotek Ltd (TBL), a Hyderabad-based vaccine manufacturing company, is negotiating with certain multinational drug companies to sell its 100 percent subsidiary - Transgene Vaccine. TBL specialises in making Hepatitis-B vaccine. TBL has appointed India Securities to find a buyer. TBL is currently setting up facilities to make three million doses of Hepatitis B vaccines in Hyderabad. TBL, however, has decided to sell the business only if it gets a suitable offer. (um)(psr)

Comment:

Transgene Biotek Ltd (TBL), a Hyderabad-based vaccine manufacturing company, is negotiating with certain multinational drug companies to sell its 100 percent subsidiary - Transgene Vaccine.

Asset sales & divestitures, Vaccines for Human Use, Vaccines, Transgene Biotek Ltd, Transgene Vaccine

---

Some parts © 2012 Advameg, Inc.